Global News Hubb
Advertisement Banner
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact
No Result
View All Result
Wellnessnewshubb
No Result
View All Result
Home Politics

STAT+: Emerging class of genetically targeted drugs induce remissions in leukemia patients

admin by admin
December 10, 2022
in Politics



NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about one-third of patients with advanced leukemia, according to updates Saturday from separate clinical trials.

Two biotechs — Syndax Pharmaceuticals and Kura Oncology — are developing their own versions of so-called menin inhibitors that have the potential to become effective treatments for certain types of genetically defined acute myeloid leukemia (AML), a rapidly progressing bone marrow cancer that affects adults.

Continue to STAT+ to read the full story…



Source link

Previous Post

Bank of Baroda hikes MCLR up to 30 basis effective December 12

Next Post

A flicker of hope for human rights in South Asia | Opinions

Next Post

A flicker of hope for human rights in South Asia | Opinions

Recommended

White House moves closer to a ban on menthol cigarettes

1 month ago

Axis Bank-Citibank deal likely to be completed by March 1

9 months ago

© Global News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Politics
  • Finance
  • Technology
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Politics
  • Finance
  • Technology
  • Contact

© 2022 Global News Hubb All rights reserved.